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Abstract
Background: Prevention guidelines for infants at high risk of allergic disease rec-
ommend hydrolysed formula if formula is introduced before 6 months, but evi-
dence is mixed. Adding specific oligosaccharides may improve outcomes.
Objective: To evaluate whether partially hydrolysed whey formula containing
oligosaccharides (0.8 g/100 ml) (pHF-OS) can prevent eczema in high-risk infants
[ISRCTN65195597].
Methods: We conducted a parallel-group, multicentre, randomized double-blind
controlled trial of pHF-OS vs standard cow’s milk formula. Infants with a family
history of allergic disease were randomized (stratified by centre/maternal allergy) to
active (n = 432) or control (n = 431) formula until 6 months of age if formula was
introduced before 18 weeks. Primary outcome was cumulative incidence of eczema
by 12 months in infants randomized at 0–4 weeks (375 pHF-OS, 383 control). Sec-
ondary outcomes were cumulative incidence of eczema by 12 or 18 months in all
infants randomized, immune markers at 6 months and adverse events.
Results: Eczema occurred by 12 months in 84/293 (28.7%) infants allocated to
pHF-OS at 0-4 weeks of age, vs 93/324 (28.7%) control (OR 0.98 95% CI 0.68,
1.40; P = 0.90), and 107/347 (30.8%) pHF-OS vs 112/370 (30.3%) control in all
infants randomized (OR 0.99 95% CI 0.71, 1.37; P = 0.94). pHF-OS did not
change most immune markers including total/specific IgE; however, pHF-OS
reduced cow’s milk-specific IgG1 (P < 0.0001) and increased regulatory T-cell
and plasmacytoid dendritic cell percentages. There was no group difference in
adverse events.
Conclusion: pHF-OS does not prevent eczema in the first year in high-risk
infants. The immunological changes found require confirmation in a separate
cohort.
Breastfeeding is the optimal mode of infant feeding, and early
formula introduction carries well-documented risks to infant
health and development (1, 2). Observational studies suggest
that specific variations in early diet may be associated with
allergic outcomes (3). Intervention trials in formula-fed
infants have found reduced eczema risk when formula is sup-
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Allergy
plemented with a specific oligosaccharide mix (4–6). There is
inconsistent evidence that partially hydrolysed formula
reduces eczema risk compared with intact cow’s milk formula
in high-risk infants (7–9). However, current dietary prevention
guidance includes the use of partially or extensively hydrol-
ysed formula for infants at an increased allergic disease risk
where formula is introduced before 6 months (9, 10). Impor-
tantly, previous clinical studies have not evaluated markers of
immune regulation, which may be important underlying
mechanisms for preventing allergic disease. Exclusive breast-
feeding rates are low in many countries, where early formula
introduction is common (11). In the context of low breastfeed-
ing rates and high allergic disease prevalence, the question
whether partial hydrolysis of formula, oligosaccharide supple-
mentation or both can prevent eczema is relevant.
We investigated whether a partially hydrolysed whey-domi-
nant formula supplemented with a specific oligosaccharide
mixture (pHF-OS) could reduce eczema cumulative incidence
(as primary outcome) in infants at high risk of allergic dis-
ease who receive formula milk before age of 4 weeks. We
also investigated whether the intervention could alter infant
immune responses (as secondary outcomes), due to evidence
that both pHF and oligosaccharides influence regulatory T
cells (12–14).
Methods
Clinical study design and oversight
The study was a double-blind, randomized, controlled paral-
lel-group nutritional intervention trial in infants at high risk
of developing allergic disease, conducted in 10 specialist pae-
diatric centres in Australia, Singapore, UK and Ireland from
April 2006 to March 2011.
Singleton infants born ≥36 weeks of gestational age and
≥2500 g were eligible for participation in the study if at least
one of their parents had a documented history of allergic dis-
ease, confirmed by means of skin prick testing or a history of
anaphylaxis. Exclusion criteria were as follows: twins, infants
with significant congenital abnormalities or severe neonatal
illness, prematurity or low birth weight, consumption of cow’s
milk formula before randomization. Pregnant women at study
centres were recruited in antenatal clinics or postnatal wards.
After signed informed consent, women with or without their
partner underwent skin prick testing if necessary, to confirm
eligibility. Infants of eligible women were assessed soon after
birth to confirm eligibility. Mothers were advised to exclu-
sively breastfeed for 4–6 months according to regional/inter-
national guidance, and inclusion in the study was not
dependent on mother’s feeding intentions. The participant
information sheet did not reveal the hypothesis that one type
of infant formula may be more effective than another for pre-
venting eczema. Study visits were conducted by a trained
research nurse at 4, 8, 12, 18 weeks and 6, 12 and 18 months
of age. Details of trial ethics approvals, monitoring and regu-
latory compliance are summarized in the Online Repository
[study registration ISRCTN65195597 14th February 2006].
Randomization and blinding
A trial statistician implemented a computer-generated ran-
domization sequence in blocks of 6, stratified by study centre
and parental allergic history (maternal or dual heredity vs.
only paternal). Mothers were advised to breastfeed their
infants according to expert guidelines for allergy prevention
and to contact the study team if they wished to initiate infant
formula in the first 6 months. If this occurred before 18 weeks,
infants were randomly allocated to active or control formula
in a 1 : 1 ratio by the research nurse according to the random-
ization sequence. Active and control formulas were in coded
tins identical in appearance, and the nurse accessed a code for
each participant. Formula was labelled and coded by the clini-
cal supply manager of Nutricia Research (previously Numico
Research B.V. until November 2007; Danone Research until
October 2013), who was not otherwise involved in the study.
Participants, outcome assessors, research nurses and care pro-
viders remained blind to treatment allocation throughout the
study. After the database was cleaned and locked, the treat-
ment code was partially broken (treatment allocation X and
Y), and after completion of all analyses described in the statis-
tical analysis plan, the code was fully broken.
Nutritional intervention
Assigned study formulae were delivered to participants at
home or in hospital following randomization. If formula was
introduced after 18 weeks (‘breastfed reference group’),
infants were not randomized and received a commercially
available formula of choice. Randomized infants received
study formula until 6 months, manufactured and supplied by
Nutricia Research, Cuijk, the Netherlands. The active group
received a non-ultra-filtrated hydrolysed whey-based infant
formula to which a specific mixture of neutral scGOS and
lcFOS (ratio 9 : 1; Immunofortis, Nutricia Cuijk BV, Cuijk,
the Netherlands; 85 weight per cent) and acidic pAOS (15
weight per cent) were added. Total oligosaccharide
concentration was 0.8 g/100 ml (0.68 g/100 ml neutral;
0.12 g/100 ml acidic). The control group received a regular
intact whey protein-dominant infant formula without prebi-
otics. Both active and control formulae contained similar
long-chain polyunsaturated fatty acids.
Primary and secondary outcome assessments
The primary outcome was cumulative incidence of eczema up
to 12 months of age in infants who started formula before
4 weeks of age (‘early introduction subgroup’). Cumulative
incidence of eczema up to 12 months of age in all infants
randomized (‘all subjects randomized’) was a secondary out-
come. Infants breastfed ≥18 weeks without formula com-
prised the breastfed reference group. Other secondary
outcomes were time to eczema onset, eczema severity using
SCORAD index at first presentation, gastrointestinal tract
symptoms and immunological parameters including allergen-
specific serum immunoglobulins, regulatory T-cell (Treg) and
plasmacytoid dendritic cell (pDC) numbers and cytokine
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responses to allergen and mitogen. Stool biochemistry and
faecal microbiota outcomes will be reported separately.
Eczema diagnosis was made by study physicians using
modified Hanifin and Rajka criteria (15); severity and course
of eczema was measured by trained study nurses using
SCORAD at first presentation, 4 and 8 weeks later, then as
needed. Stool frequency and consistency and gastrointestinal
tract symptoms were assessed by parent-completed question-
naires at all study visits using Likert scales (16). Blood was
collected from randomized participants at 6 months for
immune assessment.
Immune parameters
Serum at 6 months was tested for total IgE, cow’s milk- and
hen’s egg-specific IgE and cow’s milk- and hen’s egg-specific
IgG1 and IgG4 using CAP-FEIA and ELISA. Peripheral
blood mononuclear cells (PBMCs) were collected from a sub-
group of 85 infants. Eligible infants were those enrolled at a
site able to process PBMCs (Singapore, Adelaide, Mel-
bourne, London), with sufficient blood sample drawn to
allow PBMC analysis in addition to serum analysis. PBMCs
were cryopreserved for later batched analysis. Treg and den-
dritic cell populations were analysed by flow cytometry.
PBMC culture supernatants were harvested at 48 h and anal-
ysed for the secretion of IFN-c, IL-12, IL-4, IL-13, IL-10,
IL-6, TNF-a and TGF-b after stimulation with PHA, TT,
OVA or media alone by multiplex cytokine assay. Full
details of immune laboratory methods are in the Online
Repository.
Data handling, statistical and interim analyses
Data were collected from paper Case Report Forms and
entered into an electronic database by Clinquest Europe.
Sample size: a reduction in cumulative incidence of eczema
from 30% to 20% at 12 months was considered clinically
relevant (17–19). Assuming 15% dropout, this study required
350 infants randomized before 4 weeks in each arm, to have
80% power to detect this reduction in eczema, using two-
tailed chi-squared test at a significance of 0.05. The primary
analysis data set was the ‘early introduction subgroup’, and
secondary analyses were carried out on ‘all subjects random-
ized’ and the per protocol (PP) population. PP were ‘early
introduction subgroup’ infants who continued study formula
until 18 weeks, had not consumed intact cow’s milk before
18 weeks and completed their 12-month visit before
54 weeks. Outcomes were evaluated using logistic regression
to generate OR, and Cox regression to generate HR, with
95% confidence intervals. Twelve- and 18-month assessments
were included if they occurred within a 2-week window
either side of the expected assessment date, for the analysis
of primary outcomes, that is 52  2 weeks and
78  2 weeks. Secondary binary outcomes were also anal-
ysed using logistic regression; secondary continuous out-
comes used multivariate linear regression unless stated
otherwise. All clinical analyses were adjusted for specific
stratification variables (i.e. centre, parental allergic history).
Analyses were repeated including the prespecified covariates
gender, ethnicity, mode of birth, household pet, siblings and
birth weight. Analyses were performed by Public Health
Sciences and Medical Statistics, University of Southampton,
using SAS 9.3 (SAS Institute Inc, Cary, NC, USA). Planned
interim analysis was conducted on safety and primary effi-
cacy parameters, to evaluate safety and to verify whether
assumptions underlying the sample size calculation were cor-
rect – these and statistical methods for immune outcomes are
described in the Supporting information. Formal adjustment
was not made for multiple analyses, because this can lead to
overly conservative interpretation of findings, but statistical
significance was interpreted cautiously where multiple analy-
ses were made (20).
Results
In total, 1409 parents and 1268 infants were assessed for eli-
gibility, and 1047 infants were enrolled (Fig. 1). Of these, 863
(82%) introduced formula prior to 18 weeks and were ran-
domized to control or pHF-OS formula (all subjects random-
ized), and 758 (72%) were randomized before 4 weeks (‘early
introduction subgroup’). In the early introduction subgroup,
615 (81%) infants were assessed at 12 months and 594 (78%)
at 18 months; in all subjects randomized, 714 (83%) and 688
(80%) respectively; in the breastfed group, 143 (78%) and
135 (73%). Participant characteristics are shown in Table 1.
No clinically important differences between groups were
observed at baseline, but early introduction of formula milk
was more common in Singapore, where over half of random-
ized infants but less than 10% of breastfed infants were born.
Cumulative incidence of eczema at 12 months also differed
between centres, with lower rates in Singapore – 83/375
(22.1%) at 12 months; 89/369 (24.1%) 18 months – com-
pared with all other centres – 94/242 (38.8%) at 12 months;
111/236 (47.0%) at 18 months. Parents of randomized
infants (all subjects randomized) reported median formula
intake of 570 mls per day (IQR 230, 750) at 4 weeks and
840 mls at 18 weeks (510, 1050).
Effect of the intervention on cumulative incidence of eczema
Eczema occurred by 12 months in 84/293 (28.7%) infants in
the active group, vs 93/324 (28.7%) control in the ‘early
introduction subgroup’ population (OR 0.98 95% CI 0.68,
1.40; P = 0.90; Table 2). Survival analysis using Cox regres-
sion showed no significant difference between groups in time
to first onset of eczema (Fig. 2; P = 0.81). In all subjects ran-
domized, eczema occurred by 12 months in 107/347 (30.8%)
active, vs 112/370 (30.3%) control infants (OR 0.99 95% CI
0.71, 1.37; P = 0.94; Table 3). In both populations, there was
also no significant difference in incidence of eczema by
18 months, in survival without eczema by 12 or 18 months,
or in adjusted analyses for all predefined and significant
covariates (Tables 2–3). Findings were similar for the PP
data set (Table S1). Eczema severity, expressed as median
(IQR) SCORAD at the time of first diagnosis, did not differ
in the active and control arm (14 (10, 23) and 14 (9, 23),
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Infants 
(n = 1047)
Parents screened
(n =1409)
Screen failure - premature birth (33); neither parent allergic 
(13); no written consent (50); unwilling to comply with 
protocol (86)
Infants screened
(n =1268)
Control
(n = 431)
Randomised 
before 4 weeks 
(KGI; n = 383)
Randomised 
after 4 weeks 
(n = 48)
Completed up 
to 6 months
(n = 329)
Completed up 
to 6 months
(n = 47)
Completed up 
to 12 months
(n = 324)
Completed up 
to 12 months
(n = 46)
Breastfed
Not randomised 
(n = 184)
Completed up 
to 6 months
(n = 148)
Completed up 
to 12 months
(n = 143)
Active
(n = 432)
Randomised 
before 4 weeks 
(KGI; n = 375)
Randomised 
after 4 weeks 
(n = 57)
Completed up 
to 6 months
(n = 301)
Completed up 
to 6 months
(n = 55)
Completed up 
to 12 months
(n = 293)
Completed up 
to 12 months
(n = 54)
Completed up 
to 18 months
(n = 315)
Completed up 
to 18 months
(n = 45)
Completed up 
to 18 months
(n = 135)
Completed up 
to 18 months
(n = 290)
Completed up 
to 18 months
(n = 51)
Control group reasons for dropout up to 12 
months:
Adverse event (1) 
Lost to follow-up (16)
Protocol violation (6)
Withdrew consent (7)
Serious adverse event (1) 
Other (43)
Active group reasons for dropout up to 12 
months:
Adverse event (1)
Lost to follow-up (23)
Protocol violation (7)
Withdrew consent (13)
Serious adverse event (1)
Other (53)
BF group reasons for dropout 
up to 12 months:
Adverse event (0)
Lost to follow-up (12)
Protocol violation (17)
Withdrew consent (10)
Serious adverse event (0)
Other (9)
Screen failure - premature birth (53); twins (1); significant 
congenital abnormality (6); severe neonatal illness (34); 
uncertainty over patient compliance (79)
Figure 1 CONSORT flow diagram. Note some screen failures and losses to follow up included more than one reason.
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respectively P = 0.97). In the ‘early introduction subgroup’
population, 21% with eczema had moderate–severe eczema
(SCORAD ≥25) at the time of eczema diagnosis. In the
breastfed reference group, 61/138 (44.2%) infants had eczema
by 12 months and 63/136 (46.3%) by 18 months. History of
allergic disease in both parents was present in 56/184 (30%)
in the breastfed group vs 169/863 (20%) in randomized sub-
jects.
Effect of the intervention on infant immune development
Immunoglobulin levels
Serum from all subjects randomized with serum available
was analysed for total IgE (n = 588), cow’s milk-specific IgE
(n = 574), hen’s egg-specific IgE (n = 576), cow’s milk-speci-
fic IgG1 (n = 562) and hen’s egg-specific IgG1 (n = 547).
Total and specific IgE levels did not differ between groups,
as shown in Table 4. Specific IgE exceeded 0.35 kU/l in
16% for cow’s milk and 14.5% for hen’s egg at 6 months.
Cow’s milk-specific IgG1 was significantly (P < 0.0001) lower
in the active group – median 33.1 AU, IQR (10.0, 118.4),
compared to control – median 825.8 AU, IQR (324.9,
1820.2). Hen’s egg-specific IgG1 did not differ between
groups (Fig. S1). Total IgG1, IgG4, cow’s milk- and hen’s
egg-specific IgG4 did not differ between groups (data not
shown).
Plasmacytoid dendritic cells and regulatory T cells
PBMCs were analysed from 85 infants (46 active and 39 con-
trol). Baseline characteristics of the PBMC subgroup and all
subjects randomized are shown in Table S3. Infants in the
active group had an increased CD11cloCD123whi pDC per-
centage in unstimulated (P = 0.006) and tetanus toxoid-stimu-
lated PBMC (TT; P = 0.02), but not ovalbumin-stimulated
(OVA; P = 0.17) culture compared to the control group
(Fig. 3A). No differences in mDC populations were observed
Table 1 Baseline characteristics of PATCH study participants
Control [ASR]
(N = 431)
Control [Early*]
(N = 383)
Active [ASR]
(N = 432)
Active [Early*]
(N = 375)
Breastfed
(N = 184)
Maternal age (years) 30.0 (6.5) 29.7 (6.6) 29.3 (7.0) 29.0 (7.1) 31.6 (6.6)
Maternal tertiary education (%) 134 (31) 106 (28) 127 (29) 98 (26) 115 (63)
Gestational age (weeks) 38.9 (1.3) 38.8 (1.3) 39.0 (1.3) 38.9 (1.3) 39.7 (1.3)
Male sex (%) 209 (48) 185 (48) 238 (55) 204 (54) 104 (57)
Birth weight (g) 3306 (463) 3274 (462) 3302 (486) 3272 (481) 3541 (439)
Both parents allergic (%) 90 (21) 81 (21) 79 (18) 63 (17) 56 (30)
Only mother allergic (%) 240 (56) 215 (56) 250 (58) 224 (60) 94 (51)
Only father allergic (%) 99 (23) 85 (22) 102 (24) 87 (23) 34 (18)
Caucasian ethnicity (%) 157 (38) 118 (32) 156 (38) 113 (31) 150 (88)
Asian ethnicity (%) 240 (58) 237 (64) 237 (58) 234 (65) 10 (6)
Other ethnicity (%) 14 (4) 13 (4) 17 (4) 13 (4) 11 (6)
Vaginal delivery (%) 267 (62) 237 (62) 279 (65) 246 (66) 114 (62)
Instrumental delivery (%) 32 (7) 26 (7) 37 (9) 31 (8) 19 (10)
Caesarean delivery (%) 132 (31) 120 (31) 116 (27) 98 (26) 50 (27)
Pet at home (%) 130 (30) 111 (29) 138 (32) 110 (29) 58 (32)
At least one sibling (%) 235 (55) 206 (54) 231 (53) 203 (54) 91 (49)
Australia (%) 85 (20) 73 (19) 85 (20) 69 (18) 90 (49)
Ireland (%) 27 (6) 26 (7) 26 (6) 22 (6) 12 (7)
Singapore (%) 237 (55) 234 (61) 237 (55) 236 (63) 8 (4)
UK (%) 82 (19) 50 (13) 84 (19) 48 (13) 74 (40)
ASR, all subjects randomized; *Early, early introduction subgroup (infants who introduced formula milk early and were therefore randomized
at <4 weeks of age). Continuous data are presented as mean (standard deviation).
Table 2 Effect of the intervention on incidence of eczema, in infants randomized prior to 4 weeks of age [‘early introduction subgroup’]
Control Active Effect measure (95% CI)
Adjusted effect (95% CI)
Model 1
Adjusted effect (95% CI)
Model 2
Eczema by 12 months 93/324 (28.7%) 84/293 (28.7%) OR 0.98 (0.68, 1.40)
HR 1.04 (0.77, 1.40)
OR 0.94 (0.65, 1.36)
HR 0.99 (0.73, 1.34)
OR 0.97 (0.67, 1.39)
HR 1.03 (0.77, 1.39)
Eczema by 18 months 101/315 (32.1%) 99/290 (34.1%) OR 0.88 (0.62, 1.25)
HR 0.96 (0.73, 1.27)
OR 0.84 (0.59, 1.21)
HR 0.92 (0.69, 1.23)
OR 0.88 (0.62, 1.25)
HR 0.96 (0.73, 1.27)
All analyses were adjusted for stratification variables study centre and maternal allergic history. In addition, Model 1 adjusted for all prede-
fined covariates (i.e. sex, ethnicity, mode of birth, pet exposure, presence of siblings, birth weight) and Model 2 adjusted for all covariates
that were significant in Model 1 (birth weight at 12 months, none at 18 months).
Allergy 71 (2016) 701–710 © 2016 The Authors. Allergy Published by John Wiley & Sons Ltd 705
Boyle et al. Hydrolysed formula for eczema prevention
for the three culture conditions (data not shown). Infants in
the active group had increased CD4+CD25hiFoxp3hi Treg per-
centage in PBMC cultured without stimulus (P = 0.03), with
TT (P = 0.03), but not with OVA (P = 0.28; Fig. 3B).
PBMC cytokine responses
Cytokine levels were determined in cell culture supernatants
of the PBMC subgroup. There were no significant differ-
ences in mean cytokine levels between active and control
groups, except for IL-4 (mean 0.29 pg/ml active; 0.08 pg/
ml control; P = 0.001), IL-13 (mean 1.45 pg/ml active;
0.58 pg/ml control; P = 0.06) and IFN-ɣ (mean 0.33 pg/ml
active; 0.13 pg/ml control; P = 0.054) in PBMC cultured
with medium and for TNF-a levels (mean 934.4 pg/ml
active; 505.4 pg/ml control; P = 0.03) in culture with
PHA.
Figure 2 Kaplan–Meier plot of the time to first presentation of eczema in the group that was randomized before 4 weeks of age (‘early
introduction subgroup’). There was no statistically significant difference between the groups (log–rank test: P = 0.81).
Table 3 Effect of the intervention on incidence of eczema, in all infants randomized or not randomized (‘breastfed’ group)
Control (%) Active(%)
Effect measure
(95% CI)
Adjusted effect
(95% CI) Model 1
Adjusted effect
(95% CI) Model 2 Breastfed group (%)
Eczema by
12 months
112/370 (30.3) 107/347 (30.8) OR 0.99
(0.71, 1.37)
OR 0.94
(0.67, 1.32)
OR 0.97
(0.70, 1.35)
61/138 (44.2)
Eczema by
18 months
120/360 (33.3) 124/341 (36.4) OR 0.88
(0.64, 1.22)
OR 0.84
(0.60, 1.17)
OR 0.88
(0.64, 1.22)
63/136 (46.3)
All analyses were adjusted for stratification variables study centre and maternal allergic history. In addition, Model 1 adjusted for all prede-
fined covariates (i.e. sex, ethnicity, mode of birth, pet exposure, presence of siblings, birth weight) and Model 2 adjusted for all covariates
that were significant in Model 1 (pet exposure at 12 months, none at 18 months).
Table 4 Effect of the intervention on serum immunoglobulin E profile in the group randomized before 4 weeks of age (‘early introduction
subgroup’)
Control Active P value*
Total IgE (kU/l) 9.01 (4.39, 18.60) [290] 8.55 (4.47, 16.90) [278] 0.51
Cow’s milk-specific IgE (kUa/l) 0.03 (0.01, 0.06) [292] 0.03 (0.01, 0.07) [282] 0.46
Hen’s egg IgE (kUa/l) 0.01 (0.00, 0.03) [293] 0.00 (0.00, 0.02) [283] 0.15
Data are expressed as median (25th, 75th centile) [n].
*P values were calculated using the Mann–Whitney U-test.
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Adverse events
There was no significant difference between active and con-
trol groups in the number of infants with ≥1 adverse event
(AE) or serious adverse event (SAE) (Table 5), or in total
number of AE or SAE in specific categories (Tables S3 and
S4). In the breastfed group, there were fewer participants
with ≥1AE or SAE. Tables S5–S7 contain further details of
specific adverse events, gastrointestinal tract symptoms and
growth.
Discussion
Main findings
In this multicentre international randomized controlled trial,
we found no evidence that a partially hydrolysed, whey-
dominant infant formula, supplemented with a specific
oligosaccharide mixture, reduced incidence of eczema at 12
and 18 months in high-risk infants, compared with standard
cow’s milk formula. These findings contrast with some previ-
ous studies suggesting that hydrolysed formula or prebiotics
alone may reduce eczema risk in formula-fed infants (4–7).
We also found no effect on total or specific IgE levels, or a
range of other immune markers at 6 months. We did find
some positive immune effects; however because no adjust-
ments have been made for multiple comparisons, these
immune findings should be interpreted with caution. We
found that infants in the intervention group had significantly
lower levels of IgG1 against cow’s milk and increased per-
centages of Treg and pDC in both unstimulated and tetanus
toxoid-stimulated cultures as compared to control infants.
This supports the concept that infant dietary exposures may
influence immune development, although these specific
changes require confirmation in a separate cohort and their
relevance to longer-term health outcomes is not yet clear.
Comparison with other studies
The effect of hydrolysed infant formula intake on eczema
risk is controversial, with positive findings in one large trial
and negative findings in a separate large trial (7, 8). Consis-
tent with the negative study, our data failed to demonstrate a
protective effect of partially hydrolysed prebiotic-supplemen-
ted infant formula against eczema incidence. Two previous
trials evaluated an oligosaccharide mixture for eczema pre-
vention, one comparing a standard cow’s milk formula with
or without the same prebiotics as our study, but in a low risk
cohort (4), one comparing an extensively hydrolysed formula
with or without prebiotics in a high-risk population. The two
studies found similar reductions in eczema incidence over the
first year of life in the prebiotic-supplemented groups (4–6).
There are differences between our trial and the previous
successful prebiotic trials. First was the use of partially
hydrolysed formula, which itself may have immune effects
and therefore interact with prebiotic effects and this may
alter any effect of prebiotics on eczema risk (14). If the
impact of prebiotics is primarily on moderation of the
immune response to dietary antigens, it may be more appro-
priate to combine exposure to nonhydrolysed proteins to
achieve optimal long-term benefit. Second, this study
Figure 3 Plasmacytoid dendritic cell (pDC) and regulatory T-cell
(Treg) numbers in subjects receiving active or control formula
(n = 92). The geometric mean percentage of all DCs that stained
CD11clo CD123whi (A) and the geometric mean percentage of all
CD4+ T cells that stained CD25hiFoxP3hi (B) after 48-h culture in
medium, with tetanus toxoid (TT) or with ovalbumin (OVA), are
shown. Bars are 95% confidence interval. P values are for two-
sided t-test.
Table 5 Adverse events from enrolment to 18-month follow-up
Control
(n = 431)
(%)
Active
(n = 432)
(%) P
Breastfed
(n = 184) (%)
No. participants
with ≥1 adverse
events
406 (94.2) 400 (92.6) 0.34 154 (83.7)
No. with ≥1 related
adverse event
130 (30.2) 114 (26.4) 0.22 –
No. with ≥1 serious
adverse event
92 (21.3) 81 (18.8) 0.34 19 (10.3)
No. with ≥1 related
serious adverse
event
2 (0.5) 8 (1.9) 0.11 –
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included non-European study sites with very low breastfeed-
ing rates and other environmental and genetic differences –
however, our findings were similar across sites, suggesting
that inclusion of non-European study sites cannot explain the
discrepant findings alone. Overall, our data cast doubt on the
concept of hypo-allergenicity through hydrolysis of infant
formula, and the role of prebiotics, at least in relation to
influencing eczema.
While early feeding with pHF-OS was associated with
reduced cow’s milk IgG1 at 6 months, no effect on OVA
IgG1 or any allergen-specific IgE was observed. Although
IgE is considered to be the key immunoglobulin in the patho-
genesis of allergic sensitization and allergic diseases, early
food-specific IgG1 has also been found to correlate with later
development of allergic disorders. Children who were sensi-
tized (21) or asthmatic (22) at 5 years had higher hen’s egg-
specific IgG1 in early life. In addition, high-risk infants with
high food-specific IgG1 were more likely to develop inhalant-
specific IgE, compared with subjects with low food-specific
IgG1 (21, 23, 24). These findings suggest that raised food-
specific IgG1 could represent a predictive biomarker for
future allergic disease, in high-risk infants. This may have
been mediated by the hydrolysis rather than prebiotics
because hen’s egg-specific IgG1 was not altered, and others
have also reported that hydrolysis can reduce cow’s milk-spe-
cific IgG1 (25). The increased pDC and Treg percentage in
infants receiving pHF-OS is consistent with increased tolero-
genic immune responses, as both cell types play an important
role in programming and regulating immune responses (26)
and reducing the risk of Th2-mediated allergic immune
responses (27). While it is not possible to distinguish the indi-
vidual effects of hydrolysate and prebiotic, it is possible that
both components contributed to the observed immune
effects. In a mouse model of cow’s milk allergy, hydrolysed
formula feeding increased mesenteric lymph node suppressor
Foxp3+ Treg cell number that could confer protective effects
to na€ıve recipient mice (14). The specific oligosaccharide mix-
ture used in our study was shown to modulate the CD25+ T
regulatory cell compartment in mice (12, 13). Overall, the
nature and relevance of the immune changes seen requires
confirmation in a separate population.
Strengths and limitations
The concept of hypo-allergenicity in relation to infant milk
formulae should now be re-evaluated. Recent insights indi-
cate that the primary abnormality in eczema is a skin barrier
defect. Allergic sensitization is a secondary phenomenon
which increases the severity and longevity of atopic disorders
(28). Thus, interventions that reduce sensitization and/or
induce tolerance may be more important for long-term out-
comes. Our study showed that the pHF-OS did not reduce
early eczema, but suggested that pHF-OS was hypo-antigenic
and had immune modulatory effects including increased regu-
latory T-cell numbers which may protect against risk of later
allergic diseases such as asthma and allergic rhinitis. Further
studies are now required to confirm these immune findings
and to establish whether they are associated with longer-term
health implications.
The strength of our study is that of a well-conducted inter-
national multicentre trial, testing a pragmatic intervention.
The disadvantage of combining two different interventions in
one treatment arm is that we are not able to distinguish sepa-
rate effects for each intervention (partially hydrolysed for-
mula and prebiotic supplementation) – it is therefore
possible, albeit unlikely, that the interventions interacted to
lead to no clinical effect, whereas separate use of one of the
interventions might have resulted in a different outcome. Our
analyses of PBMC phenotype and function were limited by
relatively small numbers, and findings must be interpreted
cautiously as they were not corrected for multiple compar-
isons, and the study set-up necessitated the use of cryopre-
served cells which can influence PBMC phenotype and
function (29). Our study took place in a variety of settings in
different countries, so the findings are likely to be generaliz-
able to a range of settings. They may not be generalizable to
infants without a family history of allergic disease and are
not relevant to populations or individuals who do not use
cow’s milk-based infant formula in the first 18 weeks of life.
Conclusions
In summary, we found no evidence that a partially hydrol-
ysed formula containing a specific mixture of oligosaccha-
rides influences eczema incidence to 18 months, or total/
specific IgE at 6 months, in high-risk infants fed a cow’s
milk-based formula milk in the first 18 weeks of life. These
findings contrast with some previous studies which found
reduced eczema in infants fed partially hydrolysed formula
or prebiotics alone. Studies in new populations are needed to
confirm the lower levels of CM-IgG1 and increase in Treg
and pDC seen in this study, and establish whether they are
relevant to longer-term health outcomes.
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